Watch these experts discuss updates in the use of immunotherapy in melanoma, including novel approaches and immunotherapy in the adjuvant setting.
This activity is intended for oncologists, dermatologists, and pathologists.
The goal of this activity is to discuss both the practicalities of using checkpoint inhibitors in melanoma and the emergence of new immunotherapeutic strategies.
Approximate Time to Complete: 30 minutes
Credit Available: Nov. 13, 2017 - Nov. 13, 2018
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the mechanisms of action of approved immunotherapeutic regimens for the management of metastatic melanoma
- Have increased knowledge regarding the mechanisms of action of investigational immunotherapeutic agents alone or in combination
- Have increased knowledge regarding the strategies to address challenges in the management of metastatic melanoma